BiotechTube

NEOD001 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AL Amyloidosis

Conditions

AL Amyloidosis

Trial Timeline

Mar 1, 2016 → Mar 1, 2018

NCT ID
NCT02632786

About NEOD001 + Placebo

NEOD001 + Placebo is a phase 2 stage product being developed by Prothena for AL Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02632786. Target conditions include AL Amyloidosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02632786Phase 2Completed

Competing Products

20 competing products in AL Amyloidosis

See all competitors
ProductCompanyStageHype Score
ZN-d5Zentalis PharmaceuticalsPhase 1/2
33
VELCADEJohnson & JohnsonPhase 1/2
41
ABBV-383 (Etentamig)AbbViePhase 1/2
41
Venetoclax + Dexamethasone + DaratumumabAbbViePhase 1/2
41
Eplontersen Solution for InjectionAstraZenecaPhase 1
33
Treatment of transthyretin (ATTR) amyloidosis in observational study settingAstraZenecaPre-clinical
23
Carfilzomib + DexamethasoneAmgenPhase 1
32
IdelalisibGilead SciencesPhase 2
51
TafamidisPfizerPre-clinical
22
TafamidisPfizerPre-clinical
22
Fx-1006APfizerPhase 2
51
tafamidisPfizerPre-clinical
22
Cyclophosphamide + Dexamethasone + Elotuzumab + LenalidomideBristol Myers SquibbPhase 2
51
IsatuximabBristol Myers SquibbPhase 2
51
Bortezomib + Cyclophosphamide + Dexamethasone + IsatuximabSanofiPhase 1
32
Bendamustine Hydrochloride + IsatuximabSanofiPhase 2
51
NC-503 (Anti-amyloidotic (AA) Agent)GSK plcPhase 2/3
64
NTLA-2001 + PlaceboRegeneron PharmaceuticalsPhase 3
76
LinvoseltamabRegeneron PharmaceuticalsPhase 1/2
40
ALN-TTR01 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
30

Other Products from Prothena

Birtamimab + Standard of Care ChemotherapyPhase 3
69
NEOD001Phase 3
69
NEOD001Phase 2
44
NEOD001Phase 2
44
NEOD001Phase 1/2
33